A new drug called amycretin has shown it can help reduce body weight in two early-phase clinical trials. The drug, which ...

After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

Novo Nordisk is likely to draw investor attention on Monday after the company said it is moving forward with the oral and ...

Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...

Separately, Novo Nordisk presented early data for its oral amycretin program. In Phase I and Ib/IIa trials, amycretin ...

Chief Executive Antonio Filosa shuffled responsibilities within the Jeep parent company and he retained the role of head of North America and American brands. The electric-car maker launches a ...

A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few ...

Find insight on Novo Nordisk, Bumrungrad Hospital, Riverstone Holdings, and more in the latest Market Talks covering Health ...